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Abstract.  We present the first evidence that adhesion 
mediated by a member of the cadherin gene family 
can be regulated by a G  protein-coupled receptor. We 
show that activating the M3 muscarinic acetylcholine 
receptor (mAChR) rapidly induces E-cadherin-medi- 
ated adhesion in a  small cell lung carcinoma (SCLC) 
cell line.  This response is inhibited by E-cadherin an- 
tibodies, and does not occur in another SCLC cell line 
which expresses functional mAChR but reduced levels 
of E-cadherin.  Protein kinase C  may be involved, 
since phorbol  12-myristate  13-acetate also induces 
E-cadherin-mediated  aggregation.  Immunofluorescence 
analyses indicate that mAChR activation does not 
grossly alter E-cadherin  surface expression or localiza- 
tion at areas of cell-cell contact,  suggesting mAChR 
activation may increase E-cadherin binding activity. 
Our findings suggest that G protein-coupled receptors 
may regulate processes involving cadherin-mediated 
adhesion,  such as embryonic development, neurogene- 
sis, and cancer metastasis. 
C 
ELL adhesion molecules participate  in  a  variety  of 
biological processes. Because altered expression  or 
activity of these molecules may disrupt normal cell 
functioning,  determining  how adhesion is regulated  is im- 
portant for understanding  both normal and pathological  cel- 
lular events.  Neoplastic transformation  is one of the most 
well studied pathological  processes which may result in part 
from altered cell adhesion.  Anchorage-independent  growth 
and continued proliferation  in the presence of cell-cell con- 
tact (i.e., loss of contact inhibition)  are two characteristics 
of transformation  which may arise from altered  expression 
or activity of cell adhesion molecules. Consistent with this, 
several neoplasms express altered levels or different types of 
adhesion molecules compared to their normal tissue coun- 
terparts (for review see Edelman and Crossin, 1991). In ad- 
dition to participating  in transformation,  adhesion molecules 
may control  invasion  and metastasis  of transformed  cells 
(Behrens et al., 1989; Andersson et al., 1991; Johnson, 1991; 
Chen and Obrink,  1991; Frixen et al.,  1991; Vleminckx et 
al.,  1991; Zhu et al.,  1991). Thus,  the identification  of fac- 
tors which modulate cell adhesion may provide novel thera- 
peutic approaches for tumorigenesis and metastatic disease. 
Factors regulating the activity of some adhesion molecules 
have been characterized.  For example,  the binding  of cell 
surface receptors by cytokines can increase the activity or 
expression of the intercellular  adhesion molecule-1 (ICAM- 
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1) ~ (Valent et al.,  1991), the neural  cell adhesion  molecule 
(NCAM) (Roubin  et al.,  1990),  the endothelial-leukocyte 
adhesion molecule-1 (ELAM-1) (Montgomery et al., 1991), 
and members of the integrin  family (for review see Hynes, 
1992). In contrast, no cytokine has yet been identified which 
regulates  adhesion  mediated by members of the cadherin 
family. Cadherins  play an important role in embryonic com- 
paction, morphogenesis,  and neurogenesis (for review  see 
Takeichi,  1991), yet the factors which regulate  cadherin- 
mediated adhesion have not been determined. The ability of 
cadherins  to inhibit invasion and metastasis of transformed 
cells (Behrens et al., 1989; Chen and Obrink,  1991; Frixen 
et al.,  1991; Vleminckx et al., 1991) provides further moti- 
vation  to  elucidate  the  regulation  of  cadherin-mediated 
adhesion. 
Activation of protein kinase C by phorbol esters increases 
adhesion  mediated by some molecules, such as E-cadherin 
(Winkel  et al.,  1990),  ICAM-1 (Patarroyo  et al.,  1987), 
ELAM-1  (Montgomery et al.,  1991), and members of the 
integrin family (Symington et al., 1989; Wilkins et al., 1991; 
Hibbs et al.,  1991a; Valmu et al.,  1991). This suggests that 
stimulation  of cell surface receptors which are functionally 
coupled to protein kinase C may alter adhesion molecule ac- 
tivity. This possibility is supported by recent findings that 
cells transfected with receptors which functionally couple to 
1.  Abbreviations  used  in  this  paper:  mAChR,  muscarinic acetylcholine 
receptor; CEA, carcinoembryonic antigen; 4-DAMP,  4-diphenylacetoxy- 
N-methylpiperidine  methiodide; ELAM-1, endothelial-leukocyte  adhesion 
molecule-I; ICAM-1, intercellular adhesion molecule-l; NCAM, neural cell 
adhesion molecule; SCLC,  small cell lung carcinoma. 
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loss of contact inhibition (Young et al.,  1986; Julius et al., 
1989, 1990; Gutkind et al., 1991). This phenotype is induced 
by transfected muscarinic acetylcholine receptors (mAChR) 
only in the presence of agonist, indicating that second mes- 
sengers generated by the receptors  regulate this response 
(Gutkind et al.,  1991). Protein kinase C may be one of the 
required effectors, since transformation is induced only by 
the mAChR subtypes M~, M3, and M5 which activate pro- 
tein kinase C, and not by the mAChR subtypes M2 and M4 
which activate other second messenger pathways (Gutkind et 
al.,  1991). 
We are investigating factors controlling the adhesion of 
small cell lung carcinoma (SCLC) cells. SCLC cells express 
NCAM (Kibbelaar et al., 1989; Patel et al., 1989; Aletsee- 
Ufrecht et al.,  1990; Rygaard et al.,  1992),  ICAM-1 (Boyd 
et al.,  1989),  carcinoembryonic antigen (CEA) (Goslin et 
al., 1983; Bepler et al., 1989), and members of the integrin 
(Hemler et al.,  1990;  Feldman et al.,  1991) and cadherin 
(Shimoyama et al.,  1989; Rygaard et al.,  1992) gene fami- 
lies. SCLC cells also express receptors for neurotransmitters 
(Sorenson et al., 1983; Cunningham et al., 1985; Maneckjee 
and Minna,  1990;  Williams and Lennon, 1990)  and auto- 
crine growth factors (for review see Weynants et al., 1990), 
and it is  possible  that activation of these  receptors  may 
modulate the expression or activity of SCLC adhesion mole- 
cules. To investigate this, we have examined the ability of the 
M3 subtype of mAChR expressed by SCLC cells to regulate 
cell-cell adhesion. We previously reported that mAChR ac- 
tivation inhibits voltage-gated Ca  2+ channel activity (Wil- 
liams and Lermon, 1990) and causes cell cycle arrest (Wil- 
liams and Lennon, 1991) in the SCLC cell line SCC-9.  We 
now report that cell-cell adhesion increases upon mAChR 
activation in SCC-9  cells.  We have identified E-cadherin 
(also known as uvomorulin) as the adhesion molecule medi- 
ating this response. Our data indicate that the binding activ- 
ity of E-cadherin is increased by mAChR activation, and that 
protein kinase C may participate in this response. 
Our finding that mAChR activation increases E-cadherin- 
mediated adhesion provides the first evidence that E-cad- 
herin binding activity can be regulated by activating a heter- 
ologous, cell surface receptor. Additionally, this is the first 
report that activation of a neurotransmitter receptor can in- 
crease the binding activity of  a cell adhesion molecule. These 
findings  may  have important implications for our understand- 
ing of the factors which regulate embryonic compaction, 
morphogenesis, and neurogenesis, all of which involve cad- 
herin-mediated adhesion.  These findings also support the 
hypothesis that neoplastic transformation  induced by mAChR 
or other G protein-coupled receptors may involve receptor- 
mediated changes in adhesion molecule activity. Additionally, 
our data suggest a novel mechanism to induce E-cadherin- 
mediated adhesion, and thus possibly alter metastasis and 
invasion of carcinomas expressing this adhesion molecule. 
Materials and Methods 
Reagents 
The primary antibodies used in this study are described in Table I. The dis- 
parate concentrations of the primary antibodies provided by the suppliers 
prohibited using equal concentrations of the different antibodies in the as- 
says. As an alternative, an attempt was made to use maximal concentrations 
of antibodies.  To do this,  all antibodies used in a particular assay  were 
diluted by the same factor. Primary antibodies were dialyzed against RPMI 
1640 media (GIBCO BRL, Gaithersburg,  MD) before being used in func- 
tional assays  of living cells.  FITC-labeled  secondary  antibodies (Fisher 
Table L Primary Antibodies Used  in the Assays 
Stock 
Name used  Antigenic  Hybridoma  concentration 
in text  specificity  clone  Isotype*  (#g/ml)  Supplier 
c~-2  u2-integrin  P 1  E6  IgG~  NA*  Telios 
c~-L  otL-integrin  MHM24  IgGl  114  Dako 
c~-M  otM-integrin  2LPM 19C  IgG~  82  Dako 
/~- 1  ~-integrin  4B4LDC9LDH8  IgG~  1,000  Coulter 
/~-2  /~2-integrin  MHM23  IgG~  206  Dako 
Control  Keyhole  X40  IgGl  50  Becton- 
Limpet  Dickinson 
hemocyanin 
CD57  CD57  HNK- 1  IgM  12  Becton- 
Dickinson 
CEA  CEA  A5B7  IgGl  0.04  Dako 
DECMA  E-cadherin  DECMA-I  rat IgGl  9,600  Sigma 
HECD  E-cadherin  HECD-1  IgGl  500  Dr.  S,  Thacher 
Dr.  M.  Takeichi 
Leu54  ICAM- 1  LB-2  IgG2b  3  Becton- 
Dickinson 
N-cad  N-cadherin  GC-4  IgG~  2,800  Sigma 
NCAM  NCAM  MY31  IgG~  50  Becton- 
Dickinson 
P1 B5  c~3-integrin  P 1B5  IgG~  NA*  Telios 
WEHI  ICAM-1  WEHI-CAM-1  IgG2b  1,000  Dr.  J.  Fecondo 
Dr.  A. Boyd 
* All antibodies are from the mouse, except where noted. 
~: Not available. IgG concentrations are not available from the supplier. Lots used were 1A0384 (hybridoma clone PIEt) and 1A0453 (hybridoma clone PIB5). 
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anti-mouse IgM, and goat anti-rat IgG.  PMA and the inactive drug 4-c~ 
phorbol (Sigma Chem. Co., St. Louis, MO) were dissolved in anhydrous 
dimethylsulfoxide (Sigma Chem. Co.) at a stock concentration of 6 mM, 
and diluted in culture medium for assays. Carbachol, atropine, pertussis 
toxin  (Sigma  Chem.  Co.),  and  4-diphenylacetoxy-N-methylpiperidine 
methiodide  (4-DAMP)  (Research  Biochems.  Inc.,  Natick,  MA)  were 
diluted directly in culture medium. [35S]methionine in the form of Tran35S  - 
label  was  purchased  from  ICN  Biomedicals  Inc.  (Irvine,  CA).  Rat 
anti-mouse kappa light chain coupled to Sepharose 4B was purchased from 
Zymed Labs., Inc. (San Francisco, CA). Other reagents were obtained from 
sources listed in the text. 
Cell Culture 
The SCLC cell line SCC-9 line was established from a biopsy specimen of 
SCLC which had metastasized to the skin. Extensive characterization of 
this cell line (Cunningham et al., 1985; Williams and Lennon, 1990,  1991) 
indicates it is clonal and expresses mAChR of M3 subtype, but does not ex- 
press nicotinic acetylcholine receptors of the type found in skeletal muscle 
(Cunningham et al.,  1985).  The SCLC cell lines NCI-H146, NCI-H345, 
NCI-H209, NCI-H69, and NCI-H82 were obtained from the Amer. Type 
Culture Collection (Rockville, MD). All SCLC cell lines used in this study 
grow as floating aggregates in tissue culture. The SA-4B cell line is a clonal 
line of human B cells transformed with Epstein-Barr virus, as previously 
described (Williams et al., 1992). All cell lines were cultured in RPMI 1640 
medium containing 10%  calf bovine serum (Hyclone Labs., Logan UT), 
glutamine (0.3 mg/mi), penicillin (20 U/ml), and streptomycin sulfate (20 
#g/ml), at 37°C in a humidified atmosphere of 5% CO2/95% air. Cultures 
were maintained at cell densities which promoted exponential growth. 
Measurement of  lntraceUular Free Ca  2+ Concentration 
Cells were incubated in culture medium containing Indo-1 AM (4/LM) and 
pluronic (0.1%) (Molecular Probes, Inc., Eugene, OR) for 30 min at 37"C, 
diluted 1:1 with culture medium, incubated another 30 min, and washed. 
The ratio of intracellular Indo-1 fluorescence at 390 and 500 nm was mea- 
sured  with  a  Facstar-Plus  (Becton-Dickinson Immunocytometry  Sys., 
Mountain View, CA).  Ratios were converted to Ca  2+  concentrations as 
previously described (Williams and Lennon, 1990). 
Cell-Cell Adhesion Assays 
Cells were incubated in culture medium with or without antibodies (1:5 dilu- 
tion, 30 min, 37°C), and then gently shaken with or without drugs (1 h, 
37°C).  Cells were transferred to microscope slides coated with poly-L- 
lysine, fixed in Trumps solution (1% glutaraldehyde and 4 % formaldehyde 
in sodium phosphate buffer), and mounted in PBS containing glycerol (1%). 
The mean area of cell aggregates in eight microscope fields in each sample 
was determined by computer-assisted morphometry using an IBAS Image 
Analysis System (Carl Zeiss Inc., Thornwood, NY). 
Immunofluorescence Assays 
For quantitative analysis of surface proteins, cells were incubated (30 min, 
4"C) with primary antibody diluted 1:5 in PBS containing 1% BSA, washed 
twice in cold PBS/I% BSA, and incubated (30 rain, 4°C) with a 1:100 dilu- 
tion of fluorescein-labeled  secondary antibody specific for the primary anti- 
body. After washing, the cells were fixed in paraformaldehyde (1% in PBS) 
and analyzed using a fluorescence-activated cell sorter (Becton-Dickinson 
Immunocytometry Sys.). When primary antibodies specific for cadherins 
were used, PBS was replaced with Krebs buffer (118 mM NaC1, 4.7 mM 
KCI,  2  mM  CaC12, 1.2  mM  MgC12, 24.9  mM  NaHCO3,  pH  7.4). 
Nonspecific, background immunofluorescence was determined by incubat- 
ing cells with control antibody reactive with keyhole limpet hemocyanin, 
which is not expressed by human cells, followed by fluorescein-labeled sec- 
ondary antibody. The results are presented as the mean fluorescence inten- 
sity of the cell population, and as the percent of cells with fluorescence in- 
tensity greater than cells incubated with control antibody. 
For photomicroscopy, cells were incubated in culture medium in the 
presence or absence of drugs (1 h, 37"C), and then centrifuged onto cover- 
slips coated with poly-L-lysine. Cells were fixed and permeabilized in for- 
malin (3%, 30 min, 4°C) and Triton-X 100 (0.1%,  5 rain, 22°C), washed 
three times in Krebs buffer,  and incubated in Krebs buffer containing 1% 
BSA (30 min, 22°C).  After incubation with HECD or control antibody 
diluted 1:100 in Krebs buffer/l% BSA (1 h, 220C), the cells were washed 
three times and  incubated with a  1:100  dilution  of fluorescein-labeled 
anti-mouse IgG (1 h, 22°C).  After washing, cells were mounted in PBS 
containing glycerol (1%)  and p-phenylenediamine (0.1%)  and examined 
with a fluorescence microscope (Carl Zeiss, Inc.) 
Immunoprecipitation 
Cells were cultured in methionine-free  RPMI 1640 medium containing calf 
bovine serum (10%) and [35S]methionine  (50/~Ci/ml) for 16 h at 37"C, 
and lysed in lysis buffer A (1% Triton-X  100  in PBS containing 2  mM 
CaCI2,  pH 7.4) or lysis buffer B (0.5% sodium deoxycholate, 2% NP-40, 
0.2% SDS, 1 mM Na3VO4, 50 mM NaCI, 25 mM Tris-HC1,  pH 7.4) in the 
presence of protease inhibitors (50 pM PMSF, 0.1 t~g/ml Pepstatin A, and 
1 KIU/mi Aprotinin). After preclearing the lysates by incubation with rat 
anti-mouse kappa light chain coupled to Sepbarose 4]3 (1 h, 4°C), super- 
hates containing l0  s cpm were incubated (1 h, 40C) with HECD or control 
antibody diluted 1:10 in dilution buffer (10 mM Tris-HCl, 140 mM NaC1, 
2 mM CaCl2,  0.05%  Triton-X 100, 0.1% BSA, pH 8.0). The samples were 
shaken with anti-mouse kappa light chain coupled to Sepbarose 4B (1 h, 
4°C) and sequentially washed in dilution buffer, Tris-Saline (10 mM Tris- 
HC1,  140 mM NaCl, 2  mM CaCI2,  pH 8.0),  and 50 mM Tris-HCl (pH 
6.8).  Immunoprecipitates were boiled in sample buffer (50 mM Tris-HCl, 
2% SDS, 5% 2-mercaptoethanol, 10% glycerol, pH 6.8), centrifuged, and 
the resulting supernates were subjected to PAGE (5% stacking gel,  10% 
separating gel)  as  previously described (Williams and  Lennon,  1992). 
Dried gels were subjected to autoradiography. 
Results 
Expression of  Functional mAChR by SCLC Cells 
We previously demonstrated that SCC-9 cells express mAChR 
of the M3 subtype (Williams and Lennon, 1990). Functional 
activity of these receptors is indicated by a rise in intracellu- 
lar free Ca  2+ caused by the agonist carbachol, and a loss of 
this response caused by 4-DAMP, an antagonist specific for 
the M3  subtype of mAChR (Fig.  1).  We found that NCI- 
H146 cells also  exhibit changes in intracellular free Ca  2+ 
concentrations in response to carbachol and 4-DAMP, indi- 
cating the presence of functional mAChR on these cells (Fig. 
D.  The  slightly  different  Ca  2+  responses  of SCC-9  and 
NCI-H146 cells to carbachol (Fig. 1) may reflect quantitative 
differences  in  mAChR  expression  or  variations  in  Ca  2+ 
mobilization between these two cell lines. Further evidence 
that NCI-H146 cells express functional mAChR is the ability 
of carbachol to inhibit DNA synthesis in these cells (data not 
shown), similar to the effects of mAChR activation in SCC-9 
cells (Williams and Lennon, 1991). In contrast to other SCLC 
cell lines, NCI-H345 cells do not exhibit changes in intracel- 
lular  free Ca  2+  concentration (Fig.  1)  or  DNA  synthesis 
(data not shown) when exposed to mAChR agonists, indicat- 
ing NCI-H345 cells do not express functional mAChR. 
SCLC CeU-CeU Adhesion Induced by mAChR 
Activation or PMA Treatment 
We observed that cell-cell adhesion and compaction of SCC- 
9 cells increases dramatically within 15 min of exposure to 
carbachol, and remains high during the first 4 h of treatment 
(Fig. 2 C). Thereafter, cell-cell adhesion declines, reaching 
normal levels after 12 h of continuous carbachol exposure. 
Using computer-assisted morphometry, we found that maxi- 
mal concentrations of carbachol increase the size of SCC-9 
aggregates by 200-300 % (Fig. 3). This is due to mAChR acti- 
vation because atropine or 4-DAMP abrogates the effects of 
carbachol (data not shown). Surprisingly, cell-cell adhesion 
of NCI-H146 cells is not affected by carbachol (Fig. 2 D), 
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Figure 1. Functional  mAChR are expressed by SCC-9 and NCI- 
H146 cells. In SCC-9 and NCI-H146 cells, the increase in intracel- 
lular free Ca  2+ caused by carbachol (100 #M applied at 80 s) is in- 
hibited by 4-DAMP (1 #M applied at 360 s), indicating functional 
mAChR in these cells. NCI-H345 cells do not respond to carbachol 
or 4-DAMP, indicating the absence of functional mAChR. Results 
shown are representative  of four experiments. 
despite the presence of functional mAChR on these cells. 
Carbachol also does not alter adhesion of NCI-H345 cells. 
One consequence of M3 mAChR stimulation is activation 
of protein kinase C (for review see Bonner, 1989). If  protein 
kinase C  participates  in  the mAChR-mediated increase in 
SCLC adhesion, other agents which activate protein kinase 
C, such as PMA, should also increase SCLC adhesion. We 
found that PMA increases cell-cell adhesion and compac- 
tion of SCC-9 cells (Fig. 2  G), but does not alter adhesion 
of  NCI-H146  cells  (Fig.  2  H)  or  NCI-H345  cells.  The 
specificity of PMA action was confirmed by the lack of effect 
by 4a-phorbol (Fig. 2 E).  Like carbachol, PMA induces a 
rapid but transitory compaction of SCC-9 cells. Compaction 
occurs within 15 min of exposure to PMA, but is not evident 
after  12 h  of continuous PMA exposure. 
To investigate the role of pertussis toxin-sensitive G pro- 
teins in these results,  we measured the effects of pertussis 
toxin on aggregation of SCC-9 cells. We found that pertussis 
toxin (1-800 nM, 30-min preincubation) did not affect nor- 
mal aggregation of SCC-9 cells, nor did it alter aggregation 
Figure 2. Compaction of SCC-9 ceils is induced by mAChR activa- 
tion or PMA treatment.  The effects of different drugs  on SCC-9 
cells (A, C, E, and G) and NCI-HI46 cells (B, D, F, and H) are 
shown. In the absence of drugs (A and B), the cells are loosely ag- 
gregated. Carbachol (100 t~M, 1 h) induces compaction of SCC-9 
cells (C) but not NCI-HI46  cells (D). The inactive drug 4c~-phorbol 
(60 nM,  1 h) does not affect the ceils (E and F), whereas PMA (60 
nM, 1 h) induces compaction of SCC-9 cells (G) but not NCI-H146 
cells  (H). Results shown are representative  of four experiments. 
Bars, 50 #m. 
and compaction of SCC-9 cells treated with carbachol (100 
/~M,  1 h) or PMA (60 nM,  1 h). 
Identification of the Adhesion Molecule Mediating 
Drug-induced Aggregation of  SCC-9 Cells 
We hypothesized that SCC-9 cells aggregate in response to 
carbachol or PMA due to increased activity or expression of 
a  cell adhesion molecule. Low expression of this adhesion 
molecule by NCI-H146 cells may prohibit aggregation in re- 
sponse to the drugs. This hypothesis predicts that the adhe- 
sion molecule which mediates drug-induced aggregation is 
expressed more by SCC-9 cells than NCI-H146 cells• To in- 
vestigate this,  we used immunofluorescence techniques to 
compare the  surface expression of adhesion molecules by 
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Figure 3. Aggregation of SCC-9 cells is induced by mAChR activa- 
tion. Exposure to carbachol for 1 h increases the size of SCC-9 ag- 
gregates. Results shown are the mean (±1 SEM) of  eight determina- 
tions from four independent experiments. 
SCC-9 and NCI-H146 cells. Several adhesion molecules are 
expressed similarly by SCC-9 and NCI-HI46 cells, or to a 
lesser extent by SCC-9 cells (Fig. 4), suggesting these adhe- 
sion molecules do not mediate drug-induced aggregation. 
These include ot2-integrin,  /31-integrin,  NCAM,  the CD57 
epitope (which may be present on NCAM), CEA, and N-cad- 
herin (Fig. 4). There is no detectable expression of tx,-inte- 
grin,  otL-integrin,  or/32-integrin by either SCC-9  or NCI- 
H146 cells (Fig. 4). 
We  identified  several  adhesion  molecules  which  may 
mediate aggregation, since they are expressed more by SCC- 
9 cells than NCI-H146 cells (Fig. 5). Antibodies to ICAM-1 
(Leu54 and WEHI), E-cadherin (HECD and DECMA), and 
o~3-integrin (P1B5)  immunofluorescently stain SCC-9 cells 
to a  greater extent than NCI-H146 cells (Fig.  5).  Because 
each of these antibodies can inhibit aggregation of other cell 
types (Vestweber and Kemler, 1985; Patarroyo et al.,  1987; 
Boyd et al.,  1988;  Shimoyama et al.,  1989; Carter et al., 
1990),  we tested the effects of these antibodies on drug- 
induced aggregation of SCC-9 cells (Fig. 6). Aggregation of 
SCC-9 cells caused by carbachol or PMA is not altered by 
the control antibody nor by antibodies to ICAM-1  (Leu54) 
and  ot3-integrin  (PIB5)  (Fig.  6).  However,  antibodies  to 
E-cadherin (DECMA and HECD) completely inhibit aggre- 
gation induced by either carbachol or PMA (Fig.  6).  This 
strongly  suggests  that  E-cadherin  mediates  drug-induced 
aggregation of SCC-9  cells.  As  a  control experiment, we 
tested the ability of E-cadherin antibodies to inhibit PMA- 
induced aggregation of the human B cell line SA-4B, a pro- 
cess which is known to be mediated by ICAM-1  (Patarroyo 
et al.,  1987). Antibodies to E-cadherin did not alter PMA- 
induced aggregation of SA-4B cells, whereas an antibody to 
ICAM-1  (Leu54)  did  inhibit  aggregation  (Fig.  7).  This 
specificity of E-cadherin  antibodies  for inhibiting  SCC-9 
aggregation further supports the involvement of E-cadherin 
in drug-induced aggregation of SCC-9 cells.  Additionally, 
we found that E-cadherin antibodies inhibit the compaction 
and  morphological  changes  which  SCC-9  cells  undergo 
upon exposure to carbachol or PMA (Fig.  8). 
Investigations of the Mechanism of 
E-cadherin-mediated Aggregation Induced by mAChR 
Activation or PMA Treatment 
Having  identified  E-cadherin-mediated  adhesion  as  the 
Figure 4. Identification of adhesion molecules which are expressed 
similarly by SCC-9 and NCI-H146 cells, or expressed to a lesser 
extent by SCC-9 cells. SCC-9 and NCI-H146 ceils exhibit similar 
positive immunofluorescence when incubated with antibodies to 
or2 integrin (alpha-2), (31 integrin (Beta-I), NCAM (NCAM), the 
CD57 epitope (CD57), and N-cadherin (N-cad), indicating both 
cell lines express similar levels of these adhesion molecules. Anti- 
body to CEA immunofluorescently stains NCI-HI46  cells more 
than SCC-9 ceils, indicating greater CEA expression by NCI-H146 
cells. Immunofluorescent staining of SCC-9 and NCI-H146 cells by 
antibodies to txM integrin (alpha-M), CtL integrin (alpha-L), and ~2 
integrin (Beta-2) is equal to that produced by control antibody (con- 
trol), indicating lack of expression of these adhesion molecules. 
Results shown are the mean (±1 SEM) of  three independent experi- 
ments. 
event responsible for drug-induced aggregation, we next in- 
vestigated possible mechanisms by which this process could 
occur. Carbachol or PMA may cause E-cadherin to localize 
at regions of cell-cell contact, resulting in aggregation and 
compaction. However, we observed that E-cadherin is con- 
centrated  at  cell junctions  in  both drug-treated and  non- 
treated cell populations,  and  there is  no detectable gross 
change in localization due to drug treatment (Fig. 9). 
Surface  expression  of  E-cadherin  may  increase  upon 
mAChR activation or PMA treatment. The aggregation and 
compaction of  drug-treated cells precludes quantitative anal- 
yses of E-cadherin surface immunofluorescence using pho- 
Williams  ctal. Regulation of E-cadherin by Muscarinic Receptors  647 Figure 5. Identification of adhesion molecules which are expressed 
more by SCC-9 cells than  NCI-H146 cells.  SCC-9 cells are im- 
munofluorescently stained more than NCI-H146 cells by antibodies 
to ICAM-1 (Leu54  and WEHI), E-cadherin (HECD  and DECMA), 
and  ix3  integrin  (P1B5), indicating  greater  expression  of these 
adhesion  molecules by SCC-9 cells.  Results shown are the mean 
(4-  1 SEM) of three independent experiments. 
tomicroscopy.  Therefore,  we  used  fluorescence-activated 
cell sorting to quantitate immunofluorescent surface staining 
by E-cadherin antibody. We found that immunofluorescent 
staining by E-cadherin antibody is unaltered or even slightly 
reduced in cells treated with carbachol or PMA (Fig.  10). 
This suggests that drug-induced aggregation is not due to in- 
creased  surface  expression  of  E-cadherin.  Alternatively, 
some other alteration of E-cadherin,  such as phosphoryla- 
tion or association with cytoplasmic molecules may cause 
aggregation of drug-treated cells (see Discussion). 
E-cadherin Expression in SCC-9 and Other SCLC 
Cell Lines 
Although E-cadherin has previously been detected in biopsy 
specimens of SCLC using immunohistochemical techniques 
(Shimoyama et al., 1989), further characterization of E-cad- 
herin in SCLC has not been reported, To characterize E-cad- 
herin in SCC-9 and NCI-H146 cells, we immunoprecipitated 
E-cadherin  from  lysates  of  ['S]methionine-labeled  cells 
(Fig.  11). Negligible levels of E-cadherin were immunopre- 
Figure 6.  E-cadherin antibodies inhibit drug-induced  aggregation 
of SCC-9 cells. The size of SCC-9 cell aggregates is increased by 
(A) carbachol (100 #M,  1 h) or (B) PMA (60 nM,  1 h) in the ab- 
sence of antibodies (Nil). This is not significantly altered by prein- 
cubating the cells with control antibody (Control) or antibodies to 
ICAM-1 (Leu54) or a3 integrin (PIB5). Drug-induced aggregation 
is completely inhibited by antibodies to E-cadherin (DECMA and 
HECD). Results shown are the mean (+1 SEM) of three indepen- 
dent experiments. Matched pairs of t tests were used to determine 
significant differences. Other antibodies which were tested in this 
assay and found not to alter drug-induced aggregation include nor- 
mal rat IgG (2 mg/ml) and NCAM antibody (10/xg/ml). 
cipitated from NCI-H146 cells, consistent with our immuno- 
fluorescence data.  A  protein  with  the  molecular mass of 
E-cadherin (140 kD) as well as associated proteins with mo- 
lecular masses of 109 and 97 kD were immunoprecipitated 
from SCC-9 ceils lysed in buffer A  (Fig.  11  A).  Lysis of 
SCC-9 cells in buffer B yielded immunoprecipitates contain- 
ing a  140-kD protein, as well as an associated protein with 
the molecular mass of 97 kD (Fig.  11 B). In immunoblots, 
E-cadherin antibody (HECD) recognized only the  140-kD 
protein and none of the other associated proteins (data not 
shown). 
To investigate E-cadherin expression in other SCLC cell 
lines,  we  immunofluorescently stained  several  SCLC  cell 
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hibited by ICAM-1 antibodies, but not by E-cadherin antibodies. 
PMA (60 nM, 1 h) causes SA-4B cells to aggregate in the absence 
of antibodies (Nil). This is not significantly altered by control anti- 
body (Control) or antibodies to E-cadherin (DECMA and HECD). 
PMA-induced aggregation is completely inhibited by ICAM-1 anti- 
body (Leu54). Results shown are the mean (+1 SEM) of  three inde- 
pendent experiments. Matched pairs of t tests were used to deter- 
mine significant differences. 
lines with E-cadherin antibody. Although some of the SCLC 
cell lines we tested express significant levels of E-cadherin, 
none express levels as high as SCC-9 cells (Fig.  12).  None 
of these other SCLC cell lines aggregate in response to PMA 
or carbachol. 
Figure 8. E-cadherin antibody inhibits drug-induced compaction of 
SCC-9 cells. SCC-9 cells were preincubated with E-cadherin anti- 
body (DECMA,  1:5 dilution, 30 min) and exposed to (A) no drug, 
(B) carbachol (100/~M, 1 h), (C) 4o~-phorbol  (60 riM, 1 h), or (D) 
PMA (60 riM, 1 h). The cells do not compact and resemble the un- 
treated cells shown in Fig. 2 A. Similar results were obtained using 
the HECD antibody. Results shown are representative of  three inde- 
pendent experiments. Bars, 50 tzm. 
Discussion 
Our results provide the first demonstration that activation of 
a heterologous, cell surface receptor can regulate binding ac- 
tivity of E-cadherin.  Heterologous receptors regulate ex- 
pression or activity of other adhesion molecules,  such as 
B2-integrin  (Dustin  and  Springer,  1989;  Hibbs  et  al., 
1991b), but no such receptor has previously been identified 
which  regulates  E-cadherin-mediated  adhesion.  Several 
lines of evidence indicate that mAChR activation increases 
cell-cell adhesion mediated by E-cadherin. First, carbachol- 
induced aggregation occurs only in SCC-9 cells, which have 
high E-cadherin expression.  This does not occur in NCI- 
H146 cells, which have functional mAChR but express low 
levels of E-cadherin.  Secondly, the compaction of SCC-9 
cells induced by mAChR activation morphologically resem- 
bles compaction of mouse blastomeres, a process mediated 
by E-cadherin (compare Fig. 2  C with Fig.  1 in Vestweber 
and Kemler,  1985,  and Fig.  1 in Winkel et al.,  1990).  Fi- 
nally, two different E-cadherin antibodies inhibit aggregation 
and  compaction induced by mAChR  activation in  SCC-9 
cells. The two antibodies which do this (DECMA, from rat, 
and HECD, from mouse) inhibit cell-cell adhesion mediated 
by  E-cadherin  in  other  systems  (Vestweber  and  Kemler, 
1985; Shimoyama et al., 1989). The specificity of these anti- 
bodies is indicated by their inability to alter ICAM-l-medi- 
ated adhesion of SA-4B human B cells. 
We found that PMA mimics the effects of mAChR activa- 
tion in inducing E-cadherin-mediated aggregation, suggest- 
ing that protein kinase C participates in this process. Activa- 
tion of protein kinase C has previously been shown to induce 
E-cadherin-mediated  compaction  of  mouse  blastomeres 
(Winkel et al.,  1990). Based on these results, Winkel et al. 
(1990)  hypothesized that  a  cell  surface receptor which is 
functionally coupled to protein kinase C may regulate E-cad- 
herin-mediated compaction during embryonic development. 
Our  demonstration  that  M3  mAChR  can  regulate  E-cad- 
herin-mediated  compaction of SCC-9  cells  supports  this 
hypothesis. 
Recent  studies  indicate  that  pertussis  toxin-sensitive 
G proteins may regulate cellular responses involving N-cad- 
herin-mediated adhesion (Doherty et al.,  1991).  We found 
that pertussis toxin does not alter carbachol- or PMA-induced 
aggregation of SCC-9 cells, suggesting that pertussis toxin- 
sensitive G proteins are not involved in this response. This 
finding is consistent with the fact that M3 mAChR-mediated 
responses are often regulated by G proteins which are insen- 
sitive to pertussis toxin (Hulme et al.,  1990). 
We found that E-cadherin expressed by SCC-9 cells has 
an apparent molecular mass of 140 kD, associates with ac- 
cessory molecules,  and  is  concentrated at  cell junctions. 
These are similar to the characteristics of E-cadherin ex- 
pressed by other cells.  The molecular mass of E-cadherin 
has been reported to be 115-140 kD, depending On the spe- 
cies or cell type expressing the molecule (Vestweber and 
Kemler, 1985; Ozawa et al., 1989; Shimoyama et al.,  1989; 
McCrea and Gumbiner, 1991; Nagafuchi et al.,  1991). The 
proteins associated with E-cadherin in other cells include the 
a-catenins  (otE-catenin  and  o~N-catenin)  at  102-103  kD 
(Nagafuchi and Takeichi, 1989; Ozawa et al., 1989; McCrea 
and Gumbiner, 1991; Nagafuchi et al.,  1991; Hirano et al., 
1992),  13  catenin  at  88-98  kD  (Nagafuchi  and  Takeichi, 
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herin  at SCC-9 cell junctions  is 
not affected by mAChR activation 
or PMA treatment. The immuno- 
fluorescent localization of E-cad- 
herin  by HECD antibody  at the 
junctions  of SCC-9  cells  (A)  is 
not  affected  by  (B)  carbachol 
(100 t~M, 30 rain),  (C) 4c~-phor- 
bol  (60  nM,  30  rain),  or  (D) 
PMA (60 nM,  30 mill). Control 
antibody  (E) does  not immuno- 
fluorescenfly stain  SCC-9  cells. 
NCI-H146 cells  (F) are not im- 
munofluorescently  stained  by 
HECD antibody.  Results  shown 
are representative  of three  inde- 
pendent  experiments.  Phase  mi- 
crographs are shown on the right 
side of each figure. Bars, 30 #m. 
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Figure  10.  Surface expression  of E-cadherin  is not increased  by 
mAChR activation or PMA treatment of SCC-9 cells. Immunofluo- 
rescent staining of SCC-9 cells by E-cadherin antibody (HECD) is 
not increased by carbachol (100 #M, 40 rain), 4t~-phorbol (4-alpha, 
60 riM, 40 rain), or PMA (60 nM, 40 rain). Results shown are the 
mean (+1  SEM) of two independent experiments. 
1989;  Ozawa et al.,  1989;  McCrea and  Gumbiner,  1991; 
Knudson and Wheelock,  1992;  Peifer et al.,  1992),  and "y 
catenin and plakoglobin at 80-83 kD (Ozawa et al.,  1989; 
Knudson and Wheelock, 1992; Peifer et al., 1992). Addition- 
ally, proteins of 85 and 78 kD associate with E-cadherin in 
other cell types (McCrea and Gumbiner, 1991). Similar pro- 
teins may associate with E-cadherin in SCC-9 cells,  since 
proteins  of 109  and 97  kD  are immunoprecipitated from 
SCC-9 cells with E-cadherin antibodies. The types of pro- 
teins immunoprecipitated from SCC-9 cells depend on the 
lysis buffer used.  This phenomenon has been observed in 
other systems (McCrea and Gumbiner, 1991) and may reflect 
the different abilities of the lysis buffers to disrupt the physi- 
cal connection between E-cadherin and the associated pro- 
teins.  The  localization  of E-cadhedn  at  cell junctions  in 
SCC-9 cells is similar to the localized expression of E-cad- 
herin in other cells (Vestweber and Kemler, 1985; McNeill 
et al.,  1990;  Hirano et al.,  1992; Knudson and Wheelock, 
1992;  Peifer et al.,  1992). 
We did not detect any gross changes in E-cadherin expres- 
sion or surface localization in SCC-9 cells treated with car- 
bachol or PMA. This suggests that some other modification 
of E-cadherin is responsible for drug-induced aggregation. 
Increased binding activity of E-cadherin, caused by changes 
in conformation or altered association with accessory mole- 
cules, may cause SCC-9 cells to aggregate upon mAChR ac- 
tivation or PMA exposure. This is consistent with the pro- 
posal by Winkel et al. (1990) that increased binding activity 
of E-cadherin may contribute to the compaction of mouse 
blastomeres exposed to PMA.  In SCC-9 cells,  E-cadherin 
binding activity may be increased by protein kinase C-medi- 
ated phosphorylation induced by mAChR activation or PMA 
treatment. Various protein kinases, including those activated 
by phorbol esters, phosphorylate other adhesion molecules, 
The Journal of Cell Biology, Volume 121, 1993  650 Figure 11. Immunoprecipitation of E-cadherin and associated pro- 
teins  from  small  cell  lung  carcinoma  cell  lines.  [35S]methio- 
nine-labeled  cells were lysed in buffer A (A) or buffer B (B) and 
immunoprecipitated with HECD antibody (lanes 1 and 2) or con- 
trol antibody (lanes 3 and 4). NCI-HI46 cells (lanes 1 and 3) ex- 
press negligible levels of proteins specifically immunoprecipitated 
by  HECD  antibody. In  SCC-9  cells  (lanes 2  and  4),  proteins 
specifically immunoprecipitated by HECD antibody include E-cad- 
herin (140 kD) and associated proteins at 109 (A) and 97 kD (A and 
B). Results shown are representative of three independent experi- 
ments. 
such as members of the integrin family (Hirst et al.,  1986; 
Shaw et al.,  1990;  Haimovich et al.,  1991;  Hibbs et al., 
1991a;  Valmu  et al.,  1991).  Both E- and  N-cadherin are 
phosphoproteins  (Cunningham  et  al.,  1984;  Lagunowich 
and Grunwald, 1991; Matsuyoshi et al.,  1992; Sefton et al., 
1992),  and phosphorylation of E-cadherin and associated 
proteins correlates with altered cell adhesion (Matsuyoshi et 
al., 1992; Sefton et al., 1992). Because cytoskeletal associa- 
tions may regulate the binding activity of E-cadherin (for re- 
view see Takeichi,  1991),  phosphorylation of cytoskeletal 
proteins  (Naka  et  al.,  1983;  Litchfield and  Ball,  1986; 
Kawamoto et al.,  1989;  Leoncini et al.,  1989;  Beckerle, 
1990) may also result in altered E-cadherin binding activity. 
Drug-induced compaction of SCC-9  cells is  transitory, 
declining after 4 h of  continuous drug exposure. This is simi- 
l~gure 12. Surface expression of E-cadherin varies among different 
SCLC  cell lines.  E-cadherin  antibody  (HECD) immunofluores- 
cently stains the SCC-9 cell line and, to a lesser extent, the NCI- 
H209 cell line. The NCI-H146 and NCI-H345 cell lines are less 
stained, whereas the NCI-H69 and NCI-H82 cell lines are not reac- 
tive with the HECD 'antibody. Results shown are the mean (+1 
SEM) of three independent experiments. 
lar to PMA-induced compaction of embryonic cells, which 
subsides after 1.5 h  (Winkel et al.,  1990). Downregulation 
of rnAChR (Williams and Lennon,  1991) may account for 
decompaction of SCC-9 cells after prolonged mAChR acti- 
vation. Similarly, downregulation of  protein kinase C (Grove 
and Mastro,  1988)  may cause decompaction of SCC-9 or 
embryonic cells incubated with PMA for extended periods. 
Among the six SCLC cell lines we tested, only SCC-9 
cells exhibit drug-induced,  E-cadherin-mediated compac- 
tion. Low expression of E-cadherin probably accounts for 
the nonresponsiveness of most of these  SCLC  cell lines. 
However, NCI-H209 cells express fairly high levels of  E-cad- 
herin,  but  do  not  aggregate  in  response to  carbachol or 
PMA. There may be several reasons for this. First, expres- 
sion of  E-cadherin by NCI-H209 cells may be below a thresh- 
old level needed for drug-induced compaction. It has previ- 
ously been shown that cell-cell adhesion depends on the 
quantity of  an adhesion molecule expressed at the cell surface 
(Friedlander et al.,  1989).  Secondly, an accessory mole- 
cule required for functional binding activity of E-cadherin 
may be absent in NCI-H209 cells. Hirano et al. (1992) re- 
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duced by transfecting ctN-catenin in lung carcinoma PC9 
cells, which express endogenous E-cadherin and/3-catenin, 
but no a-catenin. Finally, the appropriate effector molecules 
needed for PMA-induced aggregation may not be expressed 
by NCI-H209 cells. For example, it was recently reported 
that SCLC cell lines express varying levels of protein kinase 
C isoforms, which have different substrate specificities (Bax- 
ter et al., 1992).  If a particular isoform of protein kinase C 
participates  in PMA-induced compaction of SCLC cells, 
those cell lines lacking this isoform would not respond. 
Our finding that E-cadherin and other adhesion molecules 
are variably expressed among different SCLC cell lines is 
consistent with the results of other studies. Most SCLC cell 
lines express significant levels  of a3/3~ integrin (Hemler et 
al., 1990; Feldman et al., 1991), NCAM (Kibbelaar et al., 
1989;  Patel  et  al.,  1989;  Aletsee-Ufrecht  et  al.,  1990; 
Rygaard et al.,  1992),  and the NCAM-associated epitope 
CD57 (Ball et al., 1986),  similar to the cells lines we stud- 
ied.  More  variable  expression  of ICAM-1  (Boyd  et  al., 
1989),  CEA (Goslin et al., 1983; Bepler et al.,  1989),  and 
N-cadherin  (Rygaard et al.,  1992) has been reported for 
different SCLC cell lines. A previous study demonstrated the 
expression of E-cadherin at cell junctions in SCLC biopsies 
taken from two independent cases (Shimoyama et al., 1989). 
The functions of these various adhesion molecules in SCLC 
cells are unclear. Expression of ct3/3~ integrin may allow at- 
tachment of SCLC to the extracellular matrix (Hemler et al., 
1990;  Feldman et al.,  1991). The roles of other adhesion 
molecules are less understood. For example, SCC-9 cells ex- 
press ICAM-1 but do not express its ligands, ad32 integrin 
(Makgoba et al.,  1988)  or c~M/32 integrin (Diamond et al., 
1990). These integrins are normally expressed by cells of the 
immune system (Makgoba et al.,  1988).  The reason why 
SCLC cells express a receptor for cells of  the immune system 
is not readily apparent. 
Modulation of adhesion molecule expression or activity 
may alter the metastatic and invasive capabilities of trans- 
formed cells. Several studies have demonstrated that adhe- 
sion mediated by E-cadherin restricts invasiveness of cells 
(Behrens et al., 1989; Chen and Obrink, 1991; Frixen et al., 
1991; Vleminckx et al.,  1991) and correlates with reduced 
metastatic potential (Hashimoto et al.,  1989; Bussemakers 
et al., 1992; Ruggeri et al., 1992). Based on these findings, 
Vleminckx et al. (1991) suggested that drugs which increase 
cell adhesion by inducing E-cadherin expression may pro- 
vide a new therapy for invasive and metastatic carcinomas. 
Our studies have identified another potentially therapeutic 
class of  drugs which increase E-cadherin-mediated adhesion 
by activating cell surface receptors  or  second messenger 
pathways. These drugs could potentially affect metastasis in 
several ways. Increased cell adhesion may reduce metastasis 
by prohibiting the release of cells from a  primary tumor 
mass.  Modifying  adhesion  molecule  activity  may  also 
change the location to which tumor cells metastasize. Tumor 
cells may preferentially metastasize to tissues which express 
adhesion molecules that bind the tumor cells (for review see 
Johnson, 1991; Zhu et al., 1991). Regarding this, it may be 
significant that the SCC-9 cell line was derived from a SCLC 
metastasis to the skin, which expresses E-cadherin (Whee- 
lock and Jensen, 1992). If tumor cells have increased adher- 
ence for specific tissues, they may metastasize to these tis- 
sues rather than those which are less adhesive for the tumor 
cells. 
The roles of adhesion molecules in regulating neurite out- 
growth (for review see Reichardt et al., 1989) and synapse 
formation (for review see Schubert, 1991) have recently been 
recognized. N-cadherin is widely expressed in the nervous 
system and may participate in neurogenesis (Matsunaga et 
al., 1988; Takeichi et al., 1990;  Lagunowich et al., 1992). 
Other cadherins, including E-cadherin, are also present in 
the nervous system (Takeichi  et al.,  1990).  Based on our 
finding that activation of a neurotransmitter receptor can in- 
crease cell adhesion, it is conceivable that adhesion of neu- 
ronal membranes may be stimulated by the binding of neu- 
rotransmitters.  This  hypothesis  is  attractive  because  it 
suggests a mechanism by which neurotransmitters may guide 
the migration of  developing neurons, and promote the forma- 
tion and maintenance of neuronal synapses. Several effects 
of activating mAChR in  SCC-9  cells,  such as  decreased 
voltage-gated Ca  2÷ channel activity (Williams and Lennon, 
1990)  and  altered  proliferation  (Williams  and  Lennon, 
1991), also occur in neuronal cells upon mAChR activation 
(Wanke et al., 1987; Ashkenazi et al., 1989). Thus mAChR 
activation might stimulate adhesion of neuronal ceils as it 
does SCC-9 cells. Evidence that synaptic adhesion may be 
regulated by neurotransmitters  is  provided by the  recent 
demonstration that serotonin causes endocytosis of apCAM, 
an adhesion molecule related to NCAM, in sensory neurons 
of Aplysia (Bailey et al.,  1992;  Mayford et al.,  1992). 
Our finding that mAChR activation alters the binding ac- 
tivity of E-cadherin in SCC-9 ceils has several broad-reach- 
ing implications. This system provides a novel model for in- 
vestigating the regulation of cadherin-mediated adhesion. 
Unknown factors induce fluctuations in E-cadherin-medi- 
ated adhesion during embryonic development (Winkel et al., 
1990;  Sefton et al.,  1992).  Our results are consistent with 
the hypothesis that these fluctuations may arise due to signals 
transduced by cell surface receptors. Support for this is the 
remarkable similarity between embryonic blastomere com- 
paction (winkel et al.,  1990)  and mAChR-regulated com- 
paction of SCC-9 cells. Both events are mediated by E-cad- 
herin, probably involve protein kinase C, and temporally and 
morphologically resemble each other. It is possible that the 
phosphorylation of E-cadherin which occurs immediately 
before blastomere compaction (Sefton et al., 1992) may be 
due to activation of  a cell surface receptor which functionally 
couples to protein kinase C. In analogy to SCLC cells which 
secrete autocrine growth factors (for review see Weynants et 
al., 1990), it is conceivable that embryonic cells may synthe- 
size and secrete an autocrine factor which activates a cell 
surface receptor,  inducing compaction.  The regulation of 
cadherin-mediated adhesion by cell surface receptors may 
also play a role in other biological processes, such as mor- 
phogenesis and neurogenesis.  Finally, because metastasis 
and invasion are intimately associated with cell adhesion, 
our studies suggest that modulating the activity of cell adhe- 
sion molecules by stimulating a cell surface receptor may be 
a viable approach for inhibiting metastatic disease. 
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